Loading news...
Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 12, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the strong commercial performance of Iqirvo® in its first full year on the primary biliary cholangitis (PBC) market has triggered a US$20M milestone payment from Ipsen under the companies' licensing agreement.
Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
IPSEN (OTCMKTS:IPSEY - Get Free Report) gapped up prior to trading on Wednesday. The stock had previously closed at $34.93, but opened at $36.3596. IPSEN shares last traded at $36.3596, with a volume of 136 shares changing hands. Wall Street Analyst Weigh In IPSEY has been the topic of a number of recent research
Shares of IPSEN (OTCMKTS:IPSEY - Get Free Report) crossed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $33.27 and traded as high as $35.19. IPSEN shares last traded at $35.19, with a volume of 973 shares. Wall Street Analysts Forecast Growth
IPSEN (OTCMKTS:IPSEY - Get Free Report) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $33.02 and traded as high as $35.55. IPSEN shares last traded at $35.55, with a volume of 288 shares. Wall Street Analysts Forecast Growth Several brokerages have weighed in on
Ipsen S.A. (OTCPK:IPSEY) Q3 2025 Earnings Call October 22, 2025 7:00 AM EDT Company Participants David Loew - MD, CEO & Director Aymeric Le Chatelier - Executive VP & CFO Christelle Huguet - Executive VP and Head of R&D Conference Call Participants Charles Pitman - Barclays Bank PLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Sofia Graeff Buhl-Nielsen Xian Deng - UBS Investment Bank, Research Division Victor Floch - BNP Paribas Exane, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) Attachment 2025 Half-year Financial Report_Ipsen SA
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 600,000, or about 0.72% of the share capital, over a maximum period of six months.
Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announces today that the Annual General Meeting of the Company was held on Wednesday 21 May, 2025 at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen's Iqirvo®1 has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC).
Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANCE, 30 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 21 May 2025 at 3:00 p.m.
Ipsen S.A. (OTCPK:IPSEY) Q1 2025 Results Conference Call April 16, 2025 8:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Conference Call Participants Shan Hama - Jefferies John Priestner - JPMorgan Florent Cespedes - Bernstein Xian Deng - UBS Simon Baker - Redburn Atlantic Manos Mastorakis - Deutsche Bank Alistair Campbell - RBC Laura Hindley - Morgan Stanley Operator Hello, and welcome to Ipsen's Conference Call and Webcast for the First Quarter 2025 Results. I'll now hand you over to David Loew, Ipsen's CEO.
Ipsen S.A. (OTCPK:IPSEY) Q4 2024 Earnings Call February 13, 2025 7:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Christelle Huguet - Head, R&D Conference Call Participants Xian Deng - UBS John Priestner - JPMorgan Simon Baker - Redburn Atlantic Sachin Jain - Bank of America Florent Cespedes - Bernstein Shan Hama - Jefferies Richard Parkes - BNP Paribas Laura Hindley - Morgan Stanley Operator Hello and welcome to Ipsen's Conference Call and Webcast on Full Year 2024 Results. I'll now hand you over to David Loew, Ipsen's CEO.
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA. This follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on July 26, 2024 and the U.S. FDA Accelerated Approval on June, 10, 2024 .
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen's Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA.
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Attachment 2024 Ipsen Half-Year Financial Report
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.